SAB Biotherapeutics (NASDAQ:SABS) Stock Price Up 3.8%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was up 3.8% during trading on Tuesday . The company traded as high as $4.50 and last traded at $4.09. Approximately 14,549 shares changed hands during trading, an increase of 4% from the average daily volume of 13,979 shares. The stock had previously closed at $3.94.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a report on Tuesday, April 16th. Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a report on Tuesday, April 16th.

SAB Biotherapeutics Stock Up 3.8 %

The company has a 50 day simple moving average of $4.61 and a 200 day simple moving average of $3.49. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.45 and a current ratio of 5.45.

Institutional Trading of SAB Biotherapeutics

Institutional investors have recently modified their holdings of the company. Pathstone Family Office LLC purchased a new position in SAB Biotherapeutics in the third quarter valued at approximately $319,000. Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter worth $1,259,000. BVF Inc. IL acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter worth $6,310,000. Finally, RTW Investments LP purchased a new position in shares of SAB Biotherapeutics in the 4th quarter valued at $6,310,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.